Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | ADH4 | P08319 | 1/20 | 0.43 |
| ▸ | ADH7 | P40394 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6348875 | 1.00 | — | — | |
| SCHEMBL200216 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL2201684 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL201087 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL2201024 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL2201062 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL101122 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL21899376 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL22407240 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL26044 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 945 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986215-A | 2-Phenyl-4-acyl benzofurans, preparation and application thereof | 中国医学科学院药物研究所 | 2024-05-07 | — | — | CN | claimed |
| US-20240131040-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2024-04-25 | — | — | US | claimed |
| CN-116693479-A | BysspinA derivative, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2023-09-05 | — | — | CN | claimed |
| CN-116462658-A | Synthesis method and application of copper-catalyzed aryl sulfide salt and aryl silane cross-coupling reaction to construct novel C-C bond | 中国科学院大学 | 2023-07-21 | — | — | CN | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | claimed |
| US-20220387376-A1 | Compositions Comprising Cannabinoid Molecules that are Dissolved in Water-Miscible Solvents | NATURAL EXTRACTION SYS LLC (US) | 2022-12-08 | — | — | US | claimed |
| US-20220387351-A1 | Compositions and Methods Related to Organic Oxides | Natural Extraction Systems, LLC | 2022-12-08 | — | — | US | claimed |
| CN-114149405-A | Method for synthesizing aromatic thioether through aromatic exchange bimetallic catalysis and application | 中国科学院大学 | 2022-03-08 | — | — | CN | claimed |
| WO-2022026960-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | Natural Extraction Systems, LLC (US) | 2022-02-03 | — | — | WO | claimed |
| CN-101951921-A | Be used for the treatment of cachectic ways and means | BIONERIS AB | 2011-01-19 | — | — | CN | claimed |
| US-20100311786-A1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2010-12-09 | — | — | US | claimed |
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | claimed |
| EP-2187892-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | Bioneris AB (SE) | 2010-05-26 | — | — | EP | claimed |
| EP-2185007-A2 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | Givaudan SA (CH) | 2010-05-19 | — | — | EP | claimed |
| WO-2009038533-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | BIONERIS AB (SE) | 2009-03-26 | — | — | WO | claimed |
| WO-2009015504-A2 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2009-02-05 | — | — | WO | claimed |
| WO-2004039157-A1 | FUNGICIDE MIXTURES CONTAINING OXAZINONE | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-13 | — | — | WO | claimed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | claimed |
| US-4876027-A | Optically active composition, mesomorphic compound and liquid crystal device | CANON KABUSHIKI KAISHA (JP) | 1989-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | PYGM, GYS1, CPT1B | OPRM1 53/4885TSHR 1261/4885THRB 370/4885 |
| US-20220387376-A1 | Compositions Comprising Cannabinoid Molecules that are Dissolved in Water-Miscible Solvents | CNR2, CNR1, PHOSPHO1 | OPRM1 63/4885TSHR 4413/4885THRB 3416/4885 |
| US-20100311786-A1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | SORD, GLUL, ASNS | OPRM1 1236/4885TSHR 4769/4885THRB 3381/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | OPRM1 3826/4885TSHR 4651/4885THRB 3137/4885 |
| US-20220387351-A1 | Compositions and Methods Related to Organic Oxides | LPO, SLCO2A1, SLCO2B1 | OPRM1 26/4885TSHR 4340/4885THRB 4465/4885 |
| US-20240131040-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | CNR1, CNR2, OPRD1 | OPRM1 5/4885TSHR 1176/4885THRB 2039/4885 |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | CNR2, CNR1, FAAH | OPRM1 12/4885TSHR 2801/4885THRB 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.